Skip to main content

The impact of HS goes deeper than the skin1,2

Hidradenitis suppurativa is a chronic, progressive, systemic inflammatory disease

HS can be a difficult journey for patients

Starting a biologic treatment prior to the development of multiple irreversible tunnels and scarring is thought to improve treatment outcomes4,8

  • Early intervention may help improve outcomes4,8,9

  • Delayed intervention may lead to permanent skin damage1,8

Timely intervention

Patients on COSENTYX can find lasting HS relief10

See how COSENTYX is believed to work10

A robust safety profile10

*Limitations apply. Enrolled patients awaiting coverage for COSENTYX after 2 years may be eligible for a limited Program extension. Valid only for those with private insurance. Program provides up to $16,000 annually for the cost of COSENTYX and up to $150 per infusion (up to $1,950 annually) for the cost of administration. Co-pay support for infusion administration cost not available in Rhode Island or Massachusetts. Offer not valid under Medicare, Medicaid, or any other federal or state program. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms & Conditions for details.

Definitions 
HS, hidradenitis suppurativa; MOA, mechanism of action; QoL, quality of life.

References 
1. Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. doi:10.1038/s41572-020-0149-1 
2. Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76-90. 
3. Shah M, Sachdeva M, Alavi A. The importance of early diagnosis and treatment in hidradenitis suppurativa: case report and literature review. J Clin Cosmet Dermatol. 2020;4(2):1-4. doi:10.16966/2576-2826.151 
4. Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motilva V. Defining fistular patterns in hidradenitis suppurativa: impact on the management. Dermatol Surg. 2019;45(10):1237-1244. doi:10.1097/DSS.0000000000001916 
5. Garg A, Neuren E, Cha D, et al. Evaluating patients' unmet needs in hidradenitis suppurativa: results from the Global Survey of Impact and Healthcare Needs (VOICE) Project. J Am Acad Dermatol. 2020;82(2):366-376. doi:10.1016/j.jaad.2019.06.1301 
6. Matusiak Ł, Szczęch J, Kaaz K, et al. Clinical characteristics of pruritus and pain in patients with hidradenitis suppurativa. Acta Derm Venereol. 2018;98(2):191-194. doi:10.2340/00015555-2815 
7. Krajewski PK, Matusiak Ł, von Stebut E, et al. Quality-of-life impairment among patients with hidradenitis suppurativa: a cross-sectional study of 1795 patients. Life (Basel). 2021;8;11(1):34. doi:10.3390/life11010034 
8. Shih T, De D, Daveluy SD, et al. Real-world considerations of candidacy for biologics in hidradenitis suppurativa. Am J Clin Dermatol. 2022;23(6):749-753. 
9. Paek SY, Hamzavi I, Danby FW, Qureshi AA. Disease modification for hidradenitis suppurativa: a new paradigm. J Am Acad Dermatol. 2017;76(4):772-773. 
10. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.